drugset
drugset / Trial / NCT05937581

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

NCT05937581 ↗

Phase 1 Completed 62 enrolled CSL Behring
RandomizedSequentialQuadruple-blindTreatment

Summary

First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects

Timeline

Start
2023-09-28
Primary completion
2025-12-04
Completion
2025-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject CSL040 Unknown — Intravenous

Indications

complement deficiency